Blank Bio builds foundation models that understand RNA, the language of life. Their model powers applications across the entire R&D pipeline, from designing better drugs to running smarter clinical trials.Our first model is state-of-the-art in mRNA property prediction. It simulates costly experiments, helping partners design more effective mRNA medicines faster and cheaper. Our open-source models are being used by Sanofi & GSK.
We’re also collaborating with the Arc Institute to bring our RNA embeddings into the next generation of virtual cell models.mRNA design is just the beginning. As the model improves, we’re extending to applications like target ID, novel biomarker discovery, patient stratification, and more. We’ve spent decades applying machine learning to biology across academia (PhDs at the University of Toronto) and industry (Recursion, Deep Genomics, Amazon).
.png)
We have known CEO Jonny Hsu through our RippleX network for over five years—he was part of our initial fellowship cohorts—and have tracked his journey closely. While the valuation is higher than any of our prior Fund III entries (roughly 2x), we view this as justified by the scale of the opportunity: RNA has already proven to be a $100B+ modality through vaccine development, and Blank’s horizontal platform approach can reach commercialization faster than traditional biotech business models.